741 related articles for article (PubMed ID: 24161820)
1. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
[TBL] [Abstract][Full Text] [Related]
2. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
Satwani P; Bhatia M; Garvin JH; George D; Dela Cruz F; Le Gall J; Jin Z; Schwartz J; Duffy D; van de Ven C; Foley S; Hawks R; Morris E; Baxter-Lowe LA; Cairo MS
Biol Blood Marrow Transplant; 2012 Feb; 18(2):324-9. PubMed ID: 22079471
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
4. Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors.
Lee KH; Choi SJ; Lee JH; Lee JH; Kim DY; Seol M; Lee YS; Kang YA; Jeon M; Yun SC; Joo YD; Lee WS; Kang MJ; Kim H; Park JH; Bae SH; Ryoo HM; Kim MK; Hyun MS
Am J Hematol; 2011 May; 86(5):399-405. PubMed ID: 21523798
[TBL] [Abstract][Full Text] [Related]
5. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.
Kang HJ; Shin HY; Park JE; Chung NG; Cho B; Kim HK; Kim SY; Lee YH; Lim YT; Yoo KH; Sung KW; Koo HH; Im HJ; Seo JJ; Park SK; Ahn HS;
Biol Blood Marrow Transplant; 2010 Nov; 16(11):1582-8. PubMed ID: 20685256
[TBL] [Abstract][Full Text] [Related]
6. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children.
Jacobsohn DA; Duerst R; Tse W; Kletzel M
Lancet; 2004 Jul 10-16; 364(9429):156-62. PubMed ID: 15246728
[TBL] [Abstract][Full Text] [Related]
7. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
Schetelig J; Bornhäuser M; Kiehl M; Schwerdtfeger R; Kröger N; Runde V; Zabelina T; Held TK; Thiede C; Fauser AA; Beelen D; Zander A; Ehninger G; Siegert W;
Bone Marrow Transplant; 2004 Mar; 33(5):483-90. PubMed ID: 14716342
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H
Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864
[TBL] [Abstract][Full Text] [Related]
9. Outcome of allogeneic Hematopoietic Stem Cell Transplantation on Diamond-Blackfan anemia using busulfan-based myeloablative regimen.
Behfar M; Koochakzadeh L; Yazdanian N; Salajegheh P; Rostami T; Khodayari-Namini N; Ghavamzadeh A; Hamidieh AA
Turk J Pediatr; 2019; 61(3):407-412. PubMed ID: 31916719
[TBL] [Abstract][Full Text] [Related]
10. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.
de Lima M; Couriel D; Thall PF; Wang X; Madden T; Jones R; Shpall EJ; Shahjahan M; Pierre B; Giralt S; Korbling M; Russell JA; Champlin RE; Andersson BS
Blood; 2004 Aug; 104(3):857-64. PubMed ID: 15073038
[TBL] [Abstract][Full Text] [Related]
11. The Saudi experience in fludarabine-based conditioning regimens in patients with Fanconi anemia undergoing stem cell transplantation: excellent outcome in recipients of matched related stem cells but not in recipients of unrelated cord blood stem cells.
Ayas M; Al-Seraihi A; El-Solh H; Al-Ahmari A; Khairy A; Aldali A; Markiz S; Siddiqui K; Al-Jefri A
Biol Blood Marrow Transplant; 2012 Apr; 18(4):627-32. PubMed ID: 21871862
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis.
Kröger N; Zabelina T; Schieder H; Panse J; Ayuk F; Stute N; Fehse N; Waschke O; Fehse B; Kvasnicka HM; Thiele J; Zander A
Br J Haematol; 2005 Mar; 128(5):690-7. PubMed ID: 15725091
[TBL] [Abstract][Full Text] [Related]
13. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Lee KH; Lee JH; Lee JH; Kim DY; Seol M; Lee YS; Kang YA; Jeon M; Hwang HJ; Jung AR; Kim SH; Yun SC; Shin HJ
Blood; 2011 Sep; 118(9):2609-17. PubMed ID: 21715313
[TBL] [Abstract][Full Text] [Related]
14. A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation.
Norlin AC; Remberger M
Eur J Haematol; 2011 Jan; 86(1):57-66. PubMed ID: 20942840
[TBL] [Abstract][Full Text] [Related]
15. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.
Wall DA; Carter SL; Kernan NA; Kapoor N; Kamani NR; Brochstein JA; Frangoul H; Goyal RK; Horan JT; Pietryga D; Wagner JE; Kurtzberg J;
Biol Blood Marrow Transplant; 2005 Aug; 11(8):637-46. PubMed ID: 16041314
[TBL] [Abstract][Full Text] [Related]
16. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
18. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
Andersson BS; Valdez BC; de Lima M; Wang X; Thall PF; Worth LL; Popat U; Madden T; Hosing C; Alousi A; Rondon G; Kebriaei P; Shpall EJ; Jones RB; Champlin RE
Biol Blood Marrow Transplant; 2011 Jun; 17(6):893-900. PubMed ID: 20946966
[TBL] [Abstract][Full Text] [Related]
19. Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.
Raida L; Tucek P; Faber E; Vondrakova J; Rusinakova Z; Skoumalova I; Hubacek J; Jarosova M; Katrincsakova B; Pikalova Z; Kurfurst P; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Dec; 155(4):327-32. PubMed ID: 22336644
[TBL] [Abstract][Full Text] [Related]
20. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
